Last reviewed · How we verify
Virosomal influenza vaccine
At a glance
| Generic name | Virosomal influenza vaccine |
|---|---|
| Also known as | Inflexal V |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines (PHASE3)
- A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old (PHASE3)
- A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects (PHASE3)
- Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults (PHASE1)
- Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine (PHASE1)
- Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine (PHASE2)
- Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children (PHASE3)
- Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Virosomal influenza vaccine CI brief — competitive landscape report
- Virosomal influenza vaccine updates RSS · CI watch RSS
- Insel Gruppe AG, University Hospital Bern portfolio CI